Skip Navigation

Key Eligibility Criteria for Yescarta

  • The FDA has approved Yescarta for use in adult patients with large B-cell lymphoma after at least two other kinds of treatment failed, including DLBCL, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

    Key eligibility criteria include:

    • Confirmed diagnosis of DLBCL, primary mediastinal B cell lymphoma, high grade B-cell lymphoma, or DLBCL arising from follicular lymphoma that has either not responded to, or relapsed after, second or greater lines of systemic therapy. Therapy must have included a CD20 antibody and an anthracycline.
    • Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures)

    All patients who wish to be evaluated for Yescarta must have a referral from their oncologist to DF/BWCC’s Adult Lymphoma Program.

  • Caron Jacobson, MD, at a computer


    Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information:

    For more information about lymphoma CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.